Photobiomodulation (PBM) and low-level light therapy (LLLT) are everywhere, and so are the claims: more ATP, better recovery, fat loss, nervous system balance, strength gains… all from the same “red light” buzzword.

In this 3-paper masterclass, Dr. Mike Belkowski breaks the hype down into evidence, endpoints, and bottlenecks. You’ll get a clean, practical analysis of three very different PBM applications:

Body circumference reduction (systematic review of sham-controlled RCTs)
Autonomic nervous system regulation using HRV after infra-auricular/vagus-region PBM (randomized controlled trial)
Upper-body performance on a real-world compound lift (bench press) in collegiate athletes (double-blind repeated-measures)

Then we connect the dots: why PBM can show a strong signal in one domain, a weak signal in another, and no signal at all when the limiting factor isn’t mitochondrial energy; but coordination, sleep, stress, or recovery terrain.

Bottom line: light is real, but its application is not universal — it works when the tool matches the job.

(Educational content only, not medical advice.)

Articles Discussed in Episode:

The influence of photobiomodulation on upper body muscular performance in collegiate athletes

Effects of Acute Photobiomodulation on Heart Rate Variability in Physically Active Individuals: A Randomized and Controlled Clinical Trial

Low-level laser therapy for reducing body circumferences: a systematic review

Key Quotes From Dr. Mike:

“The PBM trap is thinking ‘more ATP’ automatically means better everything.”

“Light therapy is real, but real does not mean universal. It means context-dependent.”

“HRV is a moving target — sleep, caffeine, hydration, stress can drown out small effects.”

“If you want nervous system balance, the big levers are still sleep, rhythm, breath, and training load.”

“Ask better questions: what tissue, what depth, what dose, what endpoint?”

Key points

PBM is a signal, not a guarantee → Match the tool to the job.
Paper 1 (LLLT body contouring): short-term circumference reductions beat sham; high satisfaction; good tolerability; only 3 RCTs → promising but early.
Devices/wavelengths varied (e.g., 532 nm, 635 nm, 635–680 nm) → can’t yet define “best protocol.”
Follow-up windows were short (weeks) → durability still unknown long-term.
Mechanism proposed: adipocyte emptying/pores (adipocytolysis / lipid peroxidation) more than guaranteed fat-cell death → lifestyle may determine persistence.
Paper 2 (HRV/vagus-region PBM): acute 660 nm infraauricular PBM showed minimal HRV changes in healthy active adults; one entropy metric differed.
HRV is a noisy systems output influenced by many variables; acute PBM may be underdosed or target too indirect.
Paper 3 (bench press): PBM did not beat sham for 1RM, volume load, or soreness; baseline-to-week improvement likely learning/familiarization, not light.
As movement complexity increases, PBM’s effect may drop if the limiter is coordination/neural drive, not local muscle energetics.
Core takeaway: PBM efficacy is bottleneck-dependent—hit the bottleneck, see signal; miss it, see nothing.

Episode timeline

0:02–1:58 Setup: PBM isn’t magic—3 papers, 3 targets, 3 outcomes
1:59–14:48 Paper 1: LLLT body circumference systematic review (signal + limits)
15:19–21:47 Paper 2: Vagus-region PBM + HRV trial (mostly null; why that matters)
22:15–28:57 Paper 3: Bench press performance trial (PBM vs sham; no advantage)
29:01–35:19 Compare/contrast: endpoints, bottlenecks, evidence strength, mechanism chain length
35:38–37:23 Practical decision framework by goal (contouring vs HRV vs compound strength)
37:31–39:55 Final thesis: PBM works sometimes — context, dose, and bottleneck decide

Dr. Mike's #1 recommendations:

Deuterium depleted water: Litewater (code: DRMIKE)

EMF-mitigating products: Somavedic (code: BIOLIGHT)

Blue light blocking glasses: Ra Optics (code: BIOLIGHT)

Grounding products: Earthing.com

Stay up-to-date on social media:

Dr. Mike Belkowski:

BioLight: